Key Takeaways:
Key Takeaways:
Pfizer and Astellas reported that Talzenna (talazoparib) plus Xtandi (enzalutamide) cut the risk of radiographic progression or death by 52% in men with HRR gene-mutated metastatic castration-sensitive prostate cancer, according to Phase 3 TALAPRO-3 results presented at ASCO 2026.
"Delaying progression to castration-resistant disease, the most symptomatic and lethal phase of prostate cancer, remains a significant challenge to patients with mCSPC — especially to those with HRR gene alterations, who often experience poorer outcomes," Neeraj Agarwal, global lead investigator and Presidential Chair of Cancer Research at Huntsman Cancer Institute at the University of Utah, said.
The combination showed a hazard ratio of 0.48 (95% CI, 0.36–0.65; p<0.0001) for the primary endpoint of radiographic progression-free survival, with median follow-up exceeding 37 months. At three years, 77% of patients on Talzenna plus Xtandi remained progression-free compared with 56% on placebo plus Xtandi. Median rPFS was not reached in the treatment arm versus 46 months in the control arm. The benefit held across subgroups: patients with BRCA alterations saw a 63% risk reduction (HR 0.37), while those with non-BRCA HRR alterations saw a 43% reduction (HR 0.57).
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.5 million new cases diagnosed globally and 330,000 anticipated in the US in 2026. Up to 30% of patients with mCSPC harbor HRR gene alterations, which are linked to faster disease progression and worse outcomes. The combination is already approved in more than 60 countries for metastatic castration-resistant prostate cancer, and Pfizer is discussing the TALAPRO-3 results with global health authorities to expand the label into the earlier hormone-sensitive setting.
Interim overall survival data showed a strong trend favoring the combination (HR 0.77; 95% CI, 0.56–1.04; p=0.09), though median OS was not reached in either arm. The trial remains ongoing, with final OS analysis expected at a later date. The most common grade 3 or higher adverse event was anemia, reported in 51% of patients on Talzenna plus Xtandi versus 3% in the control group, with 5% discontinuing Talzenna due to anemia. No new safety signals were identified.
The results position Talzenna plus Xtandi as a potential new standard for HRR-mutated mCSPC, a population with limited targeted options. Investors will watch for regulatory decisions in the coming months, as a label expansion could significantly expand the addressable market for the combination beyond the current mCRPC indication.
This article is for informational purposes only and does not constitute investment advice.
